HBM contact: Dr Alexander Asam, Dr Emil Bujak
Company status: private
Inc. is a clinical-stage biopharmaceutical company focused on developing and
commercializing treatments for unmet needs in immune-mediated
dermatological diseases and conditions, or immuno-dermatology. The lead
asset "ARQ-151" is under development for topical treatment in Plaque
Psoriasis and has shown positive results in a clinical phase 2b study.
"ARQ-151“ will commence clinical Phase 3 studies in 2020. In
addition, Arcutis has various other ongoing development projects.